Bortezomib, bendamustine,and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II vertical study

Journal of Clinical Oncology

Volumn 29, Issue 25, 2011, Pages 3389-3395

  Fowler, Nathan ^a   Kahl, Brad S ^b   Lee, Peter ^c   Matous, Jeffrey V ^e   Cashen, Amanda F ^f   Jacobs, Samuel A ^g   Letzer, Jeffrey ^h   Amin, Bipinkumar ⁱ   Williams, Michael E ^j   Smith, Sonali ^k   Saleh, Alfred ^d   Rosen, Peter ^c   Shi, Hongliang ^l   Parasuraman, Sudha ^l   Cheson, Bruce D ^m  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Tower Cancer Research Foundation ^*  (United States)

^d SHARP HEALTHCARE   (United States)

^e Rocky Mountain Cancer Center   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h Kalamazoo Hematology/Oncology   (United States)

ⁱ Legacy Pharma Research   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

^k UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^l MILLENNIUM PHARMACEUTICALS INC   (United States)

^m GEORGETOWN UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; RITUXIMAB;

ADULT; AGED; ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; EXFOLIATIVE DERMATITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HERPES ZOSTER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RIGOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; PYRAZINES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052746696     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.1844     Document Type: Conference Paper

References (32)

1. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
2. Aurora V, Winter JN: Current controversies in follicular lymphoma. Blood Rev 20:179-200, 2006 (Pubitemid 44250958)
3. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
4. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005 (Pubitemid 46224008)
5. VELCADE (bortezomib) for injection: Prescribing information. Millennium Pharmaceuticals, Cambridge, MA, December 2009
6. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005 (Pubitemid 46224166)
7. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005 (Pubitemid 46237441)
8. Strauss SJ, Maharaj L, Hoare S, et al: Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24:2105-2112, 2006 (Pubitemid 46622122)
9. Friedberg JW, Cohen P, Chen L, et al: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 26:204-210, 2008
10. Blum KA, Baiocchi RA, Alinari L, et al: A phase II trial of induction plus maintenance rituximab and bortezomib in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma. Blood 112, 2008 (abstr 3053)
11. De Vos S, Goy A, Dakhil SR, et al: Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 27:5023-5030, 2009
12. Coiffier B, Osmanov E, Hong X, et al: A phase 3 trial comparing bortezomib plus rituximab with rituximab alone in patients with relapsed, rituximab-naive or -sensitive, follicular lymphoma. Blood 116:373a-374a, 2010 (abstr 857)
13. Robinson KS, Williams ME, Van der Jagt RH, et al: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26:4473-4479, 2008
14. Rummel MJ, Heine K, Bodenstein H, et al: Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients. J Clin Oncol 26:472s, 2008 (suppl; abstr 8572)
15. Wang M, Han XH, Zhang L, et al: Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22:179-185, 2008
16. Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136-1144, 2003 (Pubitemid 36323723)
17. Mitsiades N, Mitsiades CS, Richardson PG, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101:2377-2380, 2003 (Pubitemid 36302084)
18. Fenk R, Michael M, Zohren F, et al: Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 48:2345-2351, 2007 (Pubitemid 350253466)
19. Hrusovsky I, Heidtmann H-H: Combination therapy of bortezomib with low-dose bendamustine in elderly patients with advanced multiple myeloma. Blood 106, 2005 (abstr 363b)
20. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
21. Papandreou CN, Daliani DD, Nix D, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121, 2004 (Pubitemid 41095144)
22. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004 (Pubitemid 39517009)
23. Van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006 (Pubitemid 44794222)
24. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002 (Pubitemid 34525730)
25. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
26. Jost PJ, Ruland J: Aberrant NF-kappaB signaling in lymphoma: Mechanisms, consequences, and therapeutic implications. Blood 109:2700-2707, 2007 (Pubitemid 46482061)
27. Orlowski RZ: Bortezomib in combination with other therapies for the treatment of multiple myeloma. J Natl Compr Canc Netw 2:S16-S20, 2004 (suppl 4)
28. Kahl BS, Bartlett NL, Leonard JP, et al: Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study. Cancer 116:106-114, 2010
29. Cheson BD, Friedberg JW, Kahl BS, et al: Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10:452-457, 2010
30. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005
31. Goy A, Bernstein SH, McDonald A, et al: Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 51:1269-1277, 2010
32. Friedberg JW, Vose JM, Kelly JL, et al: Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter phase II clinical trial. Blood 114:381a, 2009 (abstr 924)